GeoVax Aligns Vaccine Pipeline with U.S. Global Health Strategy to Enhance National Security and Pandemic Preparedness

GeoVax Labs, Inc. announced its strong support for the newly unveiled America First Global Health Strategy by U.S. Secretary of State Marco Rubio, emphasizing how the company's vaccine pipeline aligns with strategic initiatives to strengthen American health security and national interests. The clinical-stage biotechnology company's development programs directly support the policy's pillars of making America safer, stronger, and more prosperous through domestic innovation and global health partnerships.

The strategy highlights the urgent need for rapid outbreak detection and deployment of medical countermeasures, areas where GeoVax is making significant advancements. The company is developing a continuous cell-line manufacturing technology that enhances scalability, speed, and resilience while addressing longstanding supply chain vulnerabilities in U.S. biodefense. This advanced manufacturing process supports GeoVax's MVA-based platform for rapid vaccine response against infectious disease threats including Mpox, smallpox, Zika, and hemorrhagic fever viruses.

GeoVax's GEO-MVA program for Mpox and smallpox recently received favorable scientific advice from the European Medicines Agency recommending an expedited regulatory pathway via an immuno-bridging study. This regulatory guidance provides a potentially faster path to approval while accelerating the company's commercialization and revenue opportunities. The program serves as a cornerstone of the company's strategy to develop regional supply capabilities ensuring timely and equitable access to vaccines worldwide.

The America First strategy emphasizes leveraging U.S. foreign assistance procurements to expand global access to American-made health solutions. GeoVax positions itself as a U.S.-based alternative to the existing foreign monopoly in poxvirus vaccines, supporting national security priorities while strengthening U.S. competitiveness in emerging global health markets. The company's approach directly complements U.S. goals of building resilient, country-led health systems through bilateral health agreements and integration with local health systems.

David Dodd, Chairman & CEO of GeoVax, stated that the strategy represents a historic opportunity to align U.S. innovation with global health needs while strengthening America's leadership and protecting citizens and economy. The company's multi-antigen vaccine design offers other countries efficient, cost-effective solutions that reduce dependency on fragmented, siloed programs. GeoVax's mission aligns directly with the strategy's objectives to make America safer, stronger, and more prosperous while saving lives globally through innovative vaccine and immunotherapy programs that deliver security and scalability.